Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 5/13/21 → 4/24/23 |
Funding
- Incyte Corporation: $32,697.00
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
- Munker, Reinhold (PI)